Yuval Hiltzik, DO
Pulmonary Disease · Port Jefferson Station, NYNPI 1518102607
Payments from drug & device makers
Across 932 payments — averaging $302.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$203K
- Regeneron Healthcare Solutions, Inc.$67K
- GSK$4K
- Boehringer Ingelheim$2K
- Electromed, Inc.$1K
- Sanofi$652
- plus $5K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 275 | $203,435 |
| Regeneron Healthcare Solutions, Inc. | 81 | $66,632 |
| GSK | 187 | $3,778 |
| Boehringer Ingelheim | 98 | $1,855 |
| Electromed, Inc. | 67 | $1,076 |
| Sanofi | 26 | $652 |
| Mylan Specialty L.p. | 27 | $592 |
| Grifols USA, LLC | 22 | $570 |
| Harmony Biosciences LLC | 22 | $485 |
| Baxter Healthcare | 16 | $397 |
| Advanced Respiratory, Inc | 17 | $397 |
| Insmed, Inc. | 14 | $288 |
| Vifor Pharma, Inc. | 8 | $195 |
| Verona Pharma, Inc. | 8 | $172 |
| Philips North America LLC | 8 | $140 |
| Viatris Specialty LLC | 5 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $126 |
| Teva Pharmaceuticals USA, Inc. | 5 | $117 |
| Amgen | 5 | $116 |
| Actelion Pharmaceuticals US, Inc. | 3 | $94 |
| Merck | 5 | $89 |
| Sunovion Pharmaceuticals Inc. | 4 | $76 |
| Inogen, Inc. | 3 | $59 |
| Nabriva Therapeutics, PLC | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $53 |
| Novartis | 2 | $45 |
| Pfizer | 2 | $43 |
| Johnson & Johnson(2 entities) | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| Genentech USA, Inc. | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Boston Scientific | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| AbbVie | 1 | $15 |
How this compares
$281,934 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Port Jefferson Station
- Keith HarrisPort Jefferson Station$854K
- Peter OttavioPort Jefferson Station$269K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.